Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Stock analysts at Wedbush raised their FY2021 earnings per share (EPS) estimates for Intercept Pharmaceuticals in a research note issued to investors on Friday. Wedbush analyst L. Moussatos now anticipates that the biopharmaceutical company will post earnings of $10.38 per share for the year, up from their prior estimate of $9.98. Wedbush currently has a “Outperform” rating and a $253.00 price target on the stock. Wedbush also issued estimates for Intercept Pharmaceuticals’ FY2022 earnings at $21.42 EPS.
ICPT has been the topic of a number of other reports. ValuEngine lowered Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Goldman Sachs Group lowered Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating in a research report on Wednesday, February 7th. BidaskClub raised Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 25th. Zacks Investment Research raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 19th. Finally, Citigroup set a $74.00 target price on Intercept Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, December 21st. Four research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the stock. Intercept Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $128.75.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.39) by ($1.04). Intercept Pharmaceuticals had a negative net margin of 275.18% and a negative return on equity of 267.95%. The business had revenue of $37.69 million during the quarter, compared to analyst estimates of $39.01 million. During the same period last year, the firm posted ($4.84) earnings per share. Intercept Pharmaceuticals’s quarterly revenue was up 173.1% compared to the same quarter last year.
Institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc grew its holdings in Intercept Pharmaceuticals by 48.2% during the third quarter. Legal & General Group Plc now owns 8,856 shares of the biopharmaceutical company’s stock worth $514,000 after buying an additional 2,882 shares in the last quarter. Senvest Management LLC bought a new stake in Intercept Pharmaceuticals during the third quarter worth $33,883,000. Peregrine Capital Management LLC bought a new stake in Intercept Pharmaceuticals during the fourth quarter worth $7,055,000. FNY Managed Accounts LLC bought a new stake in Intercept Pharmaceuticals during the third quarter worth $417,000. Finally, National Planning Corp grew its holdings in Intercept Pharmaceuticals by 36.2% during the third quarter. National Planning Corp now owns 71,090 shares of the biopharmaceutical company’s stock worth $4,675,000 after buying an additional 18,895 shares in the last quarter. Institutional investors and hedge funds own 74.33% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was first published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3262035/intercept-pharmaceuticals-inc-forecasted-to-earn-fy2021-earnings-of-10-38-per-share-icpt.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.